MiR-221-regulated KIT level by wild type or leukemia mutant RUNX1 : a determinant of single myeloblast fate decisions that - collectively - drives or hinders granulopoiesis by S. Rossetti et al.
Oncotarget85783www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 49), pp: 85783-85793
MiR-221-regulated KIT level by wild type or leukemia mutant 
RUNX1: a determinant of single myeloblast fate decisions that 
– collectively – drives or hinders granulopoiesis
Stefano Rossetti1, Michael J. Anauo1 and Nicoletta Sacchi1
1Department of Cancer Genetics and Genomics, Roswell Park Cancer Institute, Buffalo, NY 14263
Correspondence to: Nicoletta Sacchi, email: nicoletta.sacchi@roswellpark.org
Keywords: wild type RUNX1, RUNX1-MTG8 mutant, miR-221-KIT axis, miR-ON reporter, single myeloblast fate decisions
Received: August 10, 2017    Accepted: September 15, 2017    Published: September 23, 2017
Copyright: Rossetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
RUNX1, a master transcription factor of hematopoiesis, was shown to orchestrate 
both cell proliferation and differentiation during granulopoiesis by regulating 
microRNAs (miRs). In this study, taking advantage of the miR-ON reporter system, 
we monitored first, how the granulocyte colony stimulation factor (GCSF) temporally 
modulates the concomitant level variation of miR-221 and one of its prototypic targets, 
the stem cell factor receptor KIT, in single 32DmiR-ON-221 myeloblasts expressing wild 
type RUNX1. Second, with the same reporter system we assessed how these temporal 
dynamics are affected by the t(8;21)(q22;q22) acute myelogenous leukemia mutant 
RUNX1-MTG8 (RM8) in single 32D-RM8miR-ON-221 myeloblasts. Depending on either wild 
type, or mutant, RUNX1 transcriptional regulation, the cell-context specific miR-221-
regulated KIT level translates into differential single cell fate decisions. Collectively, 
single cell fate choices translate into either initial expansion of undifferentiated 
myeloblasts followed by terminal granulocyte differentiation, as it happens in normal 
granulopoiesis, or aggressive growth of undifferentiated myeloblasts, as it happens 
in RUNX1-MTG8-positive acute myelogenous leukemia. Increasing knowledge of 
biological changes, due to altered miRNA dynamics, is expected to have relevant 
translational implications for leukemia detection and treatment.
INTRODUCTION
Cell proliferation and differentiation are 
intimately linked processes of normal embryonic and 
postembryonic development and tissue homeostasis [1–3]. 
In hematopoiesis, a major determinant of cell fate decisions 
is RUNX1, the alpha subunit of the Core Binding Factor 
(CBF) [4–6]. RUNX1, as heterodimer with the CBF beta 
(CBFB) subunit, epigenetically regulates the transcription 
of a myriad of coding and non-coding RUNX1-target genes 
[7–9]. 
A prototypic non-coding RUNX1-target gene is 
miR-221, which plays a key role during granulopoiesis 
by regulating the expression level of the KIT receptor 
[10, 11]. KIT is a cell surface tyrosine kinase receptor 
that, upon binding the stem cell factor (SCF), activates 
signaling pathways of cell survival and proliferation [12]. 
Previously, using the 32D mouse myeloid progenitor 
model, we found that incremental exogenous KIT 
expression delays granulocytic differentiation in response 
to granulocyte colony stimulating factor (GCSF), by 
promoting cell proliferation both in a time- and GCSF-
dose-dependent manner [13]. Moreover, inhibition of 
exogenous KIT-mediated proliferation with an inhibitor 
of KIT activity (Imatinib) was shown to enable GCSF-
induced 32D granulocytic differentiation [13].
In this study we instead show that GCSF-
induced upregulation of endogenous KIT occurs in a) 
undifferentiated 32D myeloblasts expressing wild type 
RUNX1, with the potential of maturing into differentiated 
granulocytes as well as in b) undifferentiated 32D 
myeloblasts expressing the RUNX1-MTG8 (also AML1-
ETO or RUNX1T1-RUNX1, and here abbreviated as 
RM8) which are capable only of continuous growth, as 
it happens in the t(8;21)(q22;q22) acute myelogenous 
leukemia (AML). In order to test the contribution of 
single cells to either the temporal shift from myeloblast 
proliferation to granulocytic differentiation in a 32D 
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population of cells expressing wild type RUNX1, or the 
increasing proliferation potential of a 32D population 
of cells expressing the RM8 mutant, we set out to 
concomitantly assess the temporal level variation of 
endogenous miR-221-regulated KIT in single cells. 
Methods for detecting miRNAs in live cells 
include the color-tunable molecular beacon method 
[14], the RNAi-Inducible Luciferase Expression System 
(RILES) [15], and the miR-ON reporter system, which 
allows miRNA expression quantification based on green 
fluorescent protein (GFP) expression in single cells [16]. 
By using the miR-ON reporter system, we could assess 
the concomitant temporal variation of both miR-221 and 
KIT levels either in single 32DmiR-ON-221 cells with wild type 
RUNX1 or in single 32D-RM8miR-ON-221 cells with the RM8 
mutant. With this strategy we found evidence that GCSF-
induced cell proliferation delays 32DmiR-ON-221 granulocytic 
differentiation depending on the collective contribution of 
RUNX1-regulated miR-221 level in single cells, which in 
turn, determines the endogenous KIT level in each cell. 
In contrast, we found that GCSF-induced proliferation of 
32D-RM8miR-ON-221 cells, collectively due to progressive 
single cell context-specific miR-221 transcriptional 
repression, by leading to progressive single cell increase 
of KIT upregulation, hampers granulocytic differentiation. 
As shown here, depending on either normal or mutant 
RUNX1, cell-wise miR-221-regulated KIT level translates 
into individual different cell decisions. However, collectively, 
individual cell decisions lead to either initial expansion of 
wild type RUNX1 undifferentiated myeloblasts, followed 
by terminal granulocyte differentiation, as it happens in 
normal granulopoiesis, or incremental proliferation of 
undifferentiated RM8 myeloblasts, as it happens in t(8;21) 
acute myelogenous leukemia. 
RESULTS
Evidence of antithetic variation of miR-221 and 
KIT levels in single 32DmiR-ON-221 cells during 
granulopoiesis
32D myeloblasts carrying wild-type RUNX1 grow 
undifferentiated in the presence of IL-3, but undergo 
granulopoiesis when IL-3 is replaced by GCSF [17]. To 
concomitantly assess both miR-221 and KIT expression 
level variation during granulopoiesis in individual 32D 
cells, we took advantage of the ‘self-contained’ miR-ON 
reporter plasmid [16]. This plasmid exploits two OFF 
switches under the control of a bidirectional promoter: a 
tetracycline repressor (tTR-KRAB) containing a miR-
target sequence in its 3′UTR, and a GFP reporter cassette 
controlled by the tTR-KRAB repressor via a tetracycline 
operator (Tet-O). For this study we developed a miR-ON 
plasmid with a tTR-KRAB repressor flanked by a 3′UTR 
containing four sequences with perfect complementarity to 
miR-221 (Figure 1A, left schemes). Initial testing in Hela 
cells showed that the miR-ON-221 reporter was specifically 
activated by either co-transfection of exogenous miR-221, 
which leads to degradation of the tTR-KRAB repressor, 
or treatment with 1 µg/ml Doxycycline (DOX) (positive 
control), which blocks tTR-KRAB repressor binding 
to the TetO operator (Figure 1A, right panels). Next, we 
developed 32D cells stably carrying miR-ON-221 (32DmiR-
ON-221). Induction of GFP in 32DmiR-ON-221 cells nucleofected 
with miR-ON-221 was detected after treatment with DOX 
(1 µg/ml) for 7 days. GFP-positive 32DmiR-ON-221 cells were 
sorted, expanded, and tested by flow cytometry for GFP 
induction by DOX to confirm the presence of a functional 
miR-ON-221 plasmid (Figure 1B). 
To concomitantly assess both miR-221 and 
KIT expression level variation during 32DmiR-ON-221 
granulopoiesis, we analyzed GFP (for miR-221) and 
CD117 (for KIT receptor) by flow cytometry, first in 
the presence of IL-3, and subsequently in the course of 
a 12 day GCSF treatment. As shown in Figure 2A, top, 
undifferentiated 32DmiR-ON-221 cells grown in the presence 
of IL-3 displayed a subpopulation of cells (~15%) with 
miR-221low, and a subpopulation of cells (~79%) with 
miR-221high. Upon replacement of IL-3 with GCSF, the 
32D miR-221low cell subpopulation significantly increased 
from day 3 to day 12 at the expense of the 32D miR-221high 
subpopulation (Figure 2A, bottom). 
By cytofluorimetric analysis we also assessed the 
influence of miR-221 level variation on KIT receptor 
(CD117) level variation, in both 32D miR-221low (Figure 
2B, top) and 32D miR-221high (Figure 2B, bottom) cell 
subpopulations. Analysis of the CD117 geomean (i.e. 
average CD117 level) showed that a) KIT (CD117) level 
significantly increased upon GCSF treatment in both miR-
221low and miR-221high subpopulations, with a peak at day 
9 (Figure 2C, left); and b) KIT (CD117) was expressed 
significantly more in the miR-221low subpopulation relative 
to the miR-221high subpopulation between day 7 and day 
12 (Figure 2C, left). Similar differences were found when 
we analyzed the percent of KIT (CD117)-positive cells 
(relative to IL-3) in the miR-221low subpopulation versus 
the miR-221high subpopulation (Figure 2C, right). 
Thus, by monitoring the dynamics of miR-221 level 
variation in single cells with the miR-ON-reporter strategy, 
we could detect that the miR-221 level is differentially 
expressed in 32D myeloblast subpopulations in the presence 
of IL-3. However, during a 12 day GCSF treatment, the 
32D miR-221low cell subpopulation progressively increases, 
while the 32D miR-221high cell subpopulation progressively 
decreases. Consistent with the repressive role of miR-221 
on KIT receptor expression, the increase of KIT level was 
higher in the 32D miR-221low cell subpopulation relative 
to the 32D miR-221high cell subpopulation. Based on the 
overall findings in the course of 32DmiR-ON-221 granulopoiesis, 
the level of miR-221 and KIT vary dynamically, and 
antithetically, during the GCSF-induced initial myeloblast 
proliferation, and subsequent differentiation.
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Progressive KIT upregulation due to progressive 
miR-221 repression in 32D-RM8miR-ON-221 cells 
drives continuous proliferation of undifferentiated 
myeloblasts 
The t(8;21) leukemia RUNX1-MTG8 fusion 
protein (RM8), which interferes with wild type 
RUNX1 transcriptional function, by repressing miR-
221 transcription, was shown to lead to KIT receptor 
upregulation [13]. To test in 32D single cells the effects 
of RM8 on miR-221-regulated KIT level variation in 
the presence of both IL-3 and in response to a 12 day 
GCSF exposure, we developed 32D-RM8 cells stably 
expressing miR-ON-221 (32D-RM8miR-ON-221). In response 
to a 12 day GCSF treatment, differently from 32DmiR-ON-221 
cells, 32D-RM8miR-ON-221 cells were unable to undergo 
granulocytic differentiation (see lack of segmented nuclei 
in Figure 3A, top), and continued proliferating also 
Figure 1: Development of 32D cells carrying the miR-ON-221 reporter plasmid to concomitantly assess miR-221 and 
KIT levels in single cells. (A) The miR-ON-221 plasmid contains a bidirectional promoter that drives GFP under the control of the 
tetracycline operator (tetO7), as well as the tetracycline repressor-Kruppel-associated box (tTR-KRAB) carrying four tandem miR-221-
target sequences in its 3′UTR. Transient transfection of miR-ON-221 in Hela cells shows that miR-ON-221 is not active (no GFP) in the 
absence of miR-221 (top), but is activated (presence of GFP) either by co-transfection with exogenous miR-221, which binds to its target 
sequences in the 3′ UTR of the tTR-KRAB repressor mRNA leading to mRNA degradation (middle), or in the presence of doxycycline 
(1 µg/ml, 48 h), which prevents tTR-KRAB from binding the tetracycline operator (bottom). (B) Scheme showing the development of 
the 32DmiR-ON-221 stable line carrying the miR-ON-221 plasmid (left). Cytofluorimetric analysis of 32DmiR-ON-221 cells shows increased GFP 
expression in response to DOX (1 µg/ml, 7 days), thus confirming the presence and functionality of the miR-ON-221 plasmid (right).
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Figure 2: Evidence of antithetic variation of miR-221 and KIT levels in single 32DmiR-ON-221 cells during 32D 
granulopoiesis. (A) Cytofluorimetric analysis of 32DmiR-ON-221 cells at different days after GCSF treatment (representative density plots 
are shown on top) shows a progressive increase in the miR-221low subpopulation and a decrease in the miR-221high subpopulation (assessed 
as GFP % gate) relative to cells grown with IL-3 (bottom). (B and C) Cytofluorimetric analysis of 32DmiR-ON-221 cells at different days after 
GCSF treatment (representative density plots are shown in B) shows that KIT level, assessed either as geo mean (C, left) or % gate relative 
to IL-3 (C, right), is higher in the miR-221low subpopulation relative to the miR-221high subpopulation. *p < 0.05, **p < 0.01, ***p < 0.001.
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after day 5. In contrast, at this time point, the 32DmiR-ON-221 
cell proliferation curve started plateauing and diverging 
from the 32D-RM8miR-ON-221 proliferation curve (Figure 
3A, bottom). Cytofluorimetric comparison of both 32DmiR-
ON-221 and 32D-RM8miR-ON-221 cells KIT level (CD117) – 
measured either as geomean (Figure 3B, top) or percent of 
KIT-positive cells during a 12 day GCSF exposure (Figure 
3B, bottom) – showed that 32D-RM8miR-ON-221 cells had 
significantly higher KIT level (CD117) at all time points 
relative to control 32DmiR-ON-221 cells. 
Moreover, cytofluorimetric GFP analysis of 
32D-RM8miR-ON-221 cells grown in the presence of IL-3 
detected a miR-221low subpopulation (~54%) larger than the 
miR-221high subpopulation (~37%) (Figure 4, top). Similar to 
what we detected in 32DmiR-ON-221 cells (Figure 2A), over the 12 
day GCSF treatment the 32D-RM8 miR-221low subpopulation 
significantly increased, while the 32D-RM8 miR-221high 
subpopulation significantly decreased (Figure 4, bottom). 
Interestingly, when we compared the miR-221 
level in 32D-RM8miR-ON-221 vs 32DmiR-ON-221 cells by flow 
cytometry (Figure 5A), it was apparent that the reduction 
of miR-221 in response to GCSF was more drastic in 
32D-RM8miR-ON-221 (Figures 5B and 5C). Specifically, the 
miR-221low subpopulation was larger (Figure 5B, left) 
in 32D-RM8miR-ON-221 than in 32DmiR-ON-221 cells, while the 
miR-221high subpopulation was smaller (Figure 5B, right), 
Figure 3: Progressive KIT upregulation in 32D-RM8miR-ON-221 cells drives continuous proliferation of undifferentiated 
myeloblasts. (A) Giemsa staining of cytospin preparations shows that, differently from 32DmiR-ON-221 control cells, 32D cells stably 
transfected with RUNX1-MTG8 and miR-ON-221 (32D-RM8miR-ON-221) fail to undergo granulocytic differentiation (see lack of segmented 
nuclei) (top). Consistently, 32D-RM8miR-ON-221 cells continue proliferating after day 7, whereas at this stage control cells stop proliferating 
(bottom). (B) CD117 cytoflyuorimetric analysis shows that KIT level (assessed both as geo mean, shown on top, and % gate, shown at the 
bottom) increases significantly more in 32D-RM8miR-ON-221 relative to control 32DmiR-ON-221 during GCSF treatment. *p  < 0.05, ***p < 0.001.
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both under IL-3 conditions, and during the 12 day GCSF 
exposure. The different size of the miR-221low and miR-
221high subpopulations translated into a lower overall miR-
221 level (GFP Geomean) in 32D-RM8miR-ON-221 vs 32DmiR-
ON-221 cells (Figure 5C). 
Overall, our findings show that the RM8 mutant, 
which interferes with wild type RUNX1 transcriptional 
function, by progressively lowering the already low miR-
221 level in 32D-RM8miR-ON-221 single cells, exacerbates the 
GCSF-induced proliferation potential of undifferentiated 
myeloblasts by progressively increasing single cell KIT level.
DISCUSSION
Due to the high heterogeneity of both normal and 
cancer cells, one of the current challenges of biology is 
to assess how dynamic molecular changes in individual 
cells can collectively affect biological processes in a cell 
population. In this study we used the miR-ON reporter 
strategy [16], which enables to monitor the temporal 
dynamics of miRNAs in single cells. Using this strategy, 
here we show that it was possible to monitor the variation 
of wild type RUNX1 transcriptional regulation of miR-
221-regulated KIT level and how this variation translates 
into different individual myeloblast cell fate decisions. 
This, collectively, contributes to dynamic cell population 
changes. 
Using 32DmiR-ON-221 cells expressing wild type 
RUNX1, and stably transfected with the miR-ON-221 
reporter, we were able to monitor the temporal dynamics 
of level variation of both miR-221 and its target, KIT 
receptor (Figure 6A, top panel), in single cells in response 
to a 12 day GCSF cytokine exposure. MiR-221 level 
variation ranging from high to low (measured as GFP) in 
32DmiR-ON-221 cells translated into opposite level variation 
of KIT (measured as CD117) (Figure 6A, middle panel). 
At initial stages of normal 32DmiR-ON-221 granulopoiesis 
in response to a 12 day GCSF exposure, the KIT level 
was markedly high to support the expansion of the pool 
of undifferentiated myeloblasts, but it decreased at later 
stages to allow terminal granulocytic differentiation 
(Figure 6A, bottom panel). 
In order to assess the single cell level variation of 
miR-221-regulated KIT receptor expression during the 
progressive expansion of undifferentiated myeloblasts 
expressing the t(8;21) RUNX1-MTG8 (RM8) mutant, 
we used 32D-RM8miR-ON-221 cells. The RM8 mutant, by 
interfering with RUNX1, transcriptionally represses 
miR-221 transcription, thus leading to KIT upregulation 
(Figure 6B, top panel). During a 12 day GCSF exposure, 
the already low miR-221 level (measured as GFP) 
significantly decreased, while the KIT receptor level 
significantly increased (Figure 6B, middle). This 
is consistent with proliferation of undifferentiated 
32D-RM8miR-ON-221 myeloblasts (Figure 6B, bottom). In 
this respect, it is interesting to note that miR-221 and KIT 
level variation during GCSF treatment showed a divergent 
trend in 32D-RM8miR-ON-221 cells (i.e. miR-221 continued 
to decrease, while KIT continued to increase even after 
Figure 4: GCSF induces progressive miR-221 downregulation in 32D-RM8miR-ON-221 cells by expanding the miR-221low 
subpopulation and decreasing the miR-221high subpopulation. Cytofluorimetric analysis of 32D-RM8miR-ON-221 cells at different 
days after GCSF treatment (representative density plots are shown on top) shows a progressive increase in the miR-221low subpopulation 
and a decrease in the miR-221high subpopulation (assessed as GFP % gate, bottom, left) relative to 32D cells grown with IL-3. *p < 0.05, 
**p < 0.01.
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12 days) (Figure 6B, middle). In contrast, there was a 
convergent trend in 32DmiR-ON-221 cells (i.e. miR-221 tended 
to increase, while KIT tended to decrease, at the end of 
GCSF treatment) (Figure 6A, middle). Deregulation of 
the miR-221-KIT axis could be particularly relevant 
in the context of leukemia with KIT receptor activating 
mutations [18–20]. Repression of miR-221 by RM8 in 
leukemia cells with a KIT activating mutation is expected 
to exacerbate proliferation relative to RM8-positive 
leukemia cells with a non-mutated KIT.
In leukemia the single cell functional plasticity of 
the RUNX1-miR-221-KIT axis that regulates normal 
proliferation and differentiation can be undermined not 
only by the RM8 fusion protein, but also by genetic 
mutations, including other non-random cytogenetic 
rearrangements affecting RUNX1 or CBFB [21–23]. 
Indeed, we previously reported that the fusion protein 
CBFB-MYH11, resulting from the inv(16) leukemia 
chromosome inversion, induced miR-221 downregulation, 
and consequent KIT upregulation, as the RUNX1-MTG8 
fusion protein did [13]. By using the miR-ON system it is 
possible to test whether different genetic factors affecting 
the CBF subunits lead to a similar (or different) single cell 
deregulation of the miR-221-KIT axis. Moreover, there are 
other factors that can dynamically affect RUNX1 level by 
interfering with RUNX1 transcriptional function. One of 
these factors is miR-17, which regulates, and it is regulated 
by RUNX1 itself [24]. Overexpression of miR-17, 
by reducing RUNX1 level, can mimic the single cell 
effects of the RM8 leukemia genetic mutation [13]. In 
addition, recent findings in another cell context indicate 
that many other miRNAs targeting RUNX1 (e.g. miR-23b, 
miR-205, and miR-375) can play a role in determining the 
temporal variation of RUNX1 level during tumorigenesis 
[25]. Thus, the miR-ON system could be used to detect 
the hierarchical temporal dynamics of miRNAs regulating 
RUNX1 (e.g. miR-17) and RUNX1-regulated miRNAs, 
including miR-221 and other KIT-regulating miRNAs 
(e.g. miR-193a) [26, 27]. 
It is noteworthy that RUNX1 also controls 
the transcription of miRNAs critical for myeloid 
differentiation, such as miR-223 [28, 29]. Indeed, we 
found that miR-223 is transiently upregulated during 
GCSF-induced granulopoiesis of 32D cells with wild 
type RUNX1, but its upregulation is counteracted by 
stable expression of RM8 (Supplementary Figure 1). 
Thus, on one hand RM8 leads to increased KIT-mediated 
proliferation by downregulating miR-221, and on the 
other hand it counteracts miR-223-mediated granulocytic 
differentiation. By using the miR-ON system we could 
monitor the temporal modulation of these two miRNAs in 
single cells with either wild type or mutant RUNX1.
Expanding our knowledge of miRNA-induced 
dynamic biological changes, by using tools like the 
Figure 5: GCSF-induced miR-221 downregulation is exacerbated in 32D-RM8miR-ON-221 cells relative to 32DmiR-ON-221 cells. 
(A–B). Cytofluorimetric analysis of 32D-RM8miR-ON-221 vs 32DmiR-ON-221 at different days after GCSF treatment (representative histogram 
plots are shown in A) shows that the miR-221high subpopulation is larger (B, left), while the miR-221low subpopulation is smaller (B, right), 
in 32D-RM8miR-ON-221 vs. 32DmiR-ON-221 cells throughout GCSF treatment. (C) These single cell differences translate into an overall decrease 
of miR-221 (assessed as GFP geo mean) in 32D-RM8miR-ON-221 vs. 32DmiR-ON-221 cell populations. *p < 0.05, **p < 0.01, ***p < 0.001.
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miR-ON reporter system, can have relevant translational 
implications for leukemia detection and treatment. 
For instance, concomitant detection of miR-221 
downregulation and KIT upregulation could identify 
cells with a defective RUNX1-miR-221-KIT axis due to 
different factors that interfere with RUNX1 transcriptional 
function. In addition, miRNAs are emerging as promising 
targets for cancer therapy. Indeed, compounds that 
either inhibit or mimic miRNAs in cancer are being 
evaluated both in pre-clinical and clinical studies [30]. 
Thus, strategies to modulate miRNA dynamics should 
enable us to target leukemia by coordinately inhibiting 
pro-proliferative signaling pathways and inducing 
differentiation signaling pathways.
MATERIALS AND METHODS
Cells and culture conditions
HeLa cells were cultured in DMEM medium 
(Thermo Fisher, Waltham, MA) supplemented with 10% 
FBS (Thermo Fisher). 32D cells expressing wild type 
RUNX1 and GCSF receptor [17] and 32D cells carrying 
the RUNX1-MTG8 fusion protein (32D-RM8) [13], and 
Figure 6: Heterogeneous single cell functional plasticity of the RUNX1-miR-221-KIT axis translates into myeloblast 
decisions of normal and aberrant granulopoiesis. (A) In 32DmiR-ON-221 cells with functional RUNX1-miR-221-KIT axis (top), GCSF 
leads to opposite variation of miR-221 and KIT levels in single cells (middle). MiR-221-regulated KIT level initially increases to support 
the expansion of the pool of progenitor myeloblasts, but it decreases at later stages of GCSF-induced granulopoiesis to allow terminal 
granulocytic differentiation (bottom). (B) In 32D-RM8miR-ON-221 cells, expression of RUNX1-MTG8, by interfering with RUNX1 function, 
transcriptionally represses the transcription of miR-221, thus leading to KIT upregulation (top). GCSF treatment decreases the already low 
miR-221 level, resulting in further upregulation of KIT (middle). In turn, upregulation of KIT sustains proliferation of undifferentiated 
myeloblasts even at the end of the 12 day GCSF treatment (bottom).
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derived cell lines were cultured in RPMI 1640 (Thermo 
Fisher) medium supplemented with 10% heat-inactivated 
(HI) fetal bovine serum (FBS) (Thermo Fisher) and 
1 ng/ml murine IL-3 (Peprotech, Inc., Rocky Hill, NJ). 
Cells were counted daily with a Coulter Particle Counter 
(Beckman Coulter, Brea, CA) and diluted to a density of 
2 × 105 cells/ml daily. 
Development and validation of the miR-ON-221 
plasmid
The ‘self-contained’ miR-ON plasmid was kindly 
provided by Dr. Luigi Naldini, San Raffaele University, 
Milan, Italy [16]. The pMA-RQ-Bb-miR-221 plasmid, 
containing four tandem miR-221-3p-target sequences 
(5′-gaaacccagcagacaauguagc-3′) flanked by KpnI and 
XbaI restriction sites, was synthesized by Thermo Fisher. 
In order to obtain the miR-ON-221 plasmid, the four miR-
221-target sequences were cut out from the pMA-RQ-Bb-
miR-221 plasmid and sub-cloned into the KpnI and XbaI 
restriction sites (in the 3′UTR of the tTR-KRAB repressor) 
of the ‘self-contained’ miR-ON plasmid. The miR-ON-221 
plasmid was verified by sequencing with a WPRE sense 
primer (5′-tgttgggcactgacaatttcc-3′). 
In order to preliminarily test miR-ON-221 
functionality, HeLa cells were seeded in 24-well plates 
and transiently transfected with 200 ng of miR-ON-221 
construct by using Lipofectamine 2000 (Thermo Fisher). 
Twenty-four hours after transfection the medium 
was replaced with DMEM with or without 1 µg/ml 
doxycycline. Two days after doxycycline treatment, cells 
were fixed with 4% paraformaldehyde, permeabilized 
with 0.2% Triton-X 100, counterstained with DAPI, and 
analyzed with a fluorescence microscope. Hela cells were 
also transiently co-transfected with 200 ng miR-ON-221 
and 400 ng of either a plasmid expressing exogenous miR-
ON-221 or the empty vector. After 48 h, GFP fluorescence 
was analyzed with a fluorescence microscope to test if 
miR-221 was able to activate the miR-ON-221 plasmid.
Development of miR-ON-221 32D cell lines
To develop 32D cell lines stably expressing the 
miR-ON-221 plasmid, both 32D cells and 32D-RM8 cells 
were nucleofected with the miR-ON-221 plasmid using 
an Amaxa nucleofector (Lonza, Basel, Switzerland). The 
nucleofected cells were treated with 1 µg/ml doxycycline 
for seven days to induce GFP expression. GFP-positive 
cells (i.e. cells carrying miR-ON-221) were sorted by 
using a FACS Aria I cell sorter (BD, Franklin Lakes, NJ). 
Approximately 104 doxycycline-treated cells were sorted, 
using non-treated cells as a control to set the GFP-positive 
gate. The GFP-positive cells were collected and expanded 
in 32D growth medium without doxycycline and further 
tested for miR-ON functionality based on GFP induction 
after treatment with 1 µg/mL doxycycline for seven days.
Induction of 32D granulopoiesis by GCSF
To induce 32D cell granulopoiesis, IL-3 was 
replaced with 10 ng/ml human GCSF (Amgen, Thousand 
Oaks, CA). Cells were grown in culture for twelve days 
at a density of 2 × 105 cells/ml, and counted daily to 
obtain a growth curve to assess proliferation dynamics. 
Differentiation was assessed microscopically on Giemsa-
stained cytospin preparations. Cells were spun onto glass 
slides using a Cytospin 3 machine (Marshall Scientific, 
Hampton, NH), allowed to dry, and fixed with methanol 
for ten minutes. Slides were immersed in Giemsa Stain 
Modified Solution (Sigma-Aldrich, St. Louis, MO) diluted 
1:20 in double-distilled water for forty-five minutes, rinsed 
with distilled water, and imaged using a light microscope.
Flow cytometry analysis of miR-221-regulated 
KIT expression in single cells
KIT expression was assessed by cytofluorimetric 
analysis of the CD117 antigen, while miR-221 
expression was assessed based on activation of the GFP 
reporter miR-ON-221. To concomitantly measure KIT 
(CD117) and miR-221 (GFP) expression in 32DmiR-ON-221 
and 32D-RM8miR-ON-221 cells, 0.5–1 × 106 cells were 
resuspended in 95 µl blocking buffer (PBS+0.5% BSA) 
and incubated with a PE-CD117 antibody (Miltenyi 
Biotec, San Diego, CA) for twenty minutes in the dark 
on ice. Unstained cells were used as a negative control. 
After incubation, cells were washed with blocking buffer, 
resuspended in 500 µl blocking buffer, and analyzed 
by flow cytometry on an LSR Fortessa cytometer (BD 
Biosciences). Data were analyzed using WinList software. 
MiR-221 expression in the entire cell population was 
evaluated by calculating the GFP geomean. MiR-221high 
and miR-221low subpopulations were gated based on the 
presence of two distinct subpopulations with different GFP 
fluorescence in cells grown with IL-3; these gates were 
applied to each time point with GCSF to calculate the 
percentage of cells with low or high miR-221 expression. 
After GCSF treatment, KIT expression at different time 
points was calculated either as PE geomean of the total 
cell population, or as percent gate of KIT-positive cells 
relative to IL-3 (set as ~ 1%). KIT expression in the miR-
221high and miR-221low subpopulations was assessed either 
by measuring the PE geomean of the two subpopulations, 
or as percent gate of KIT-positive cells relative to IL-3 
(set to ~ 1%) within each subpopulation. The KIT geo 
mean of cells grown with GCSF was shown relative to the 
geo mean of cells grown with IL-3 (set as 1). Statistical 
significance was calculated by using the Student’s t-test. 
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